Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

KaiNETIC-3

Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 1270

NCT07284979

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Ribupatide: Dose 1n/rn/rn/rn/r
Ribupatide: Dose 2n/rn/rn/rn/r
Semaglutiden/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Ribupatide: Dose 1: endpoint not reported
  • Ribupatide: Dose 2: endpoint not reported
  • Semaglutide: endpoint not reported
  • Placebo: endpoint not reported